Skip to content
Open access

Functional CRISPR screens reveal TPL1 lncRNA as a regulator of triple-negative breast cancer hallmarks.

Jul 2026 · Journal of Advanced Research · 0 citations · 64 references
Medicine

TL;DR

TPL1 is identified as a functionally relevant lncRNA associated with TNBC growth, invasion, and molecular regulatory programs and provides a framework for further mechanistic and translational investigation.

Abstract

INTRODUCTION Despite the rapidly expanding catalog of long noncoding RNAs (lncRNAs), the functional roles of most remain poorly characterized in cancer. In triple-negative breast cancer (TNBC), an aggressive subtype with limited targeted treatment options, defining lncRNA-associated molecular mechanisms could uncover novel therapeutic vulnerabilities.

Objectives

This study aimed to systematically identify TNBC-enriched lncRNAs associated with cellular fitness, and drug response, and to functionally characterize prioritized lncRNA candidates with potential therapeutic relevance.

Methods

We generated comprehensive lncRNA annotation by integrating GENCODE, BIGTranscriptome, and MiTranscriptome databases. CRISPR-Cas9 deletion screen targeting 1,029 TNBC-enriched lncRNAs was conducted. Functional validation included proliferation assays in 2D and 3D cultures, invasion assays using an organ-on-chip model, and transcriptomic and proteomic profiling following lncRNA knockdown. Candidate lncRNA-protein associations were assessed using proteomic array analysis. miRNA expression profiling, miRanda-based interaction prediction, and Ingenuity Pathway Analysis (IPA) were used to construct candidate competing endogenous RNA (ceRNA)-like regulatory networks and downstream signaling pathways.

Results

Our CRISPR screen identified fourteen recurrent candidate lncRNA dependencies across both TNBC models, with TNBC Promoting LncRNA 1 (TPL1) emerging among the top candidates. ASO-mediated TPL1 suppression significantly reduced TNBC cell proliferation, clonogenic growth, three-dimensional growth, and invasive capacity. TPL1 was significantly overexpressed in TNBC tissues, particularly within the basal-like immune-suppressed (BLIS) subtype. RNA-FISH analysis showed nuclear/perinuclear and cytoplasmic TPL1 localization. Transcriptomic and proteomic analyses revealed suppression of pathways related to extracellular matrix-receptor interaction, focal adhesion, cell migration, and PI3K-Akt signaling following TPL1 knockdown. Proteomic array, RBPsuite, TLC-CLIP, miRNA profiling, and transcriptomic integration supported candidate protein-associated and ceRNA-like regulatory mechanisms involving TPL1.

Conclusion

This study identifies TPL1 as a functionally relevant lncRNA associated with TNBC growth, invasion, and molecular regulatory programs. These findings support TPL1 as a candidate RNA-targetable vulnerability in TNBC and provide a framework for further mechanistic and translational investigation.

Read PDF

Similar papers

Open access Aug 2026

Integrative Molecular Profiling of miR-548f-3p in Triple-Negative Breast Cancer Highlights ANP32E as a Candidate Downstream Effector

The reduction in ANP32E protein expression following miR-548f-3p restoration, together with computational, single-cell, and clinical expression evidence, supports ANP32E as an expression-responsive candidate downstream effector of miR-548f-3p in TNBC.

Samira Behroozi, Mahdieh Salimi, H. Lanjanian et al. · 1 citation
Open access Aug 2026

Long Noncoding RNAs (lncRNAs) as Biomarkers of Prognosis in TNBC and Non-TNBC Breast Cancer Patients

This computational study identifies several candidate lncRNAs associated with clinical outcomes in breast cancer, which should be interpreted as preliminary candidates, which require future validation and functional studies to determine their biological roles and evaluate their potential as prognostic biomarkers.

M. Acencio, Xin-Hui Wang, Flavia R. Rotea Mangone et al. · 0 citations
Open access Jan 2026

Integrative Pan‐Cancer Characterization of lncRNA UPK1A‐AS1 and Its Role in Hypoxia‐Associated Sorafenib Resistance in Hepatocellular Carcinoma

It is suggested that UPK1A-AS1 is a hypoxia‐inducible oncogenic lncRNA that plays dual roles in cancer, with cancer type‐dependent associations with progression and immune modulation across malignancies and mechanistically mediating hypoxia‐associated drug resistance in HCC.

Ze-Kai Li, Min Luo, Shu-Sen Fang et al. · 0 citations
Jul 2026

Transcriptomic network analysis and functional evidence identify a candidate EMT hub signature associated with nasopharyngeal carcinoma progression.

Integrative analysis identifies VIM, SNAI1, ZEB1, and FN1 as a candidate EMT-associated hub signature linked with NPC progression, prognosis, and drug response patterns, suggesting that this EMT hub network may have potential value as a prognostic biomarker panel and as a putative therapeutic vulnerability requiring fu...

Xiao-Peng Sun, Bo Kou · 0 citations
Open access Jul 2026

Integrative Multi-Omics Profiling Identifies Candidate Biomarkers in Triple-Negative Breast Cancer 2258118

This study integrates multi-omics datasets to identify candidate biomarkers that may influence TNBC progression and modulate therapeutic response and nominate CCND2 and KIF1A as candidate biomarkers and potential therapeutic targets in TNBC.

Roberto Aguilar, Victor Wang, Shane Deng · 0 citations
Aug 2026

LncRNA PCAT7 drives tumorigenesis and glycolytic reprogramming in breast cancer via the ceRNA-mediated miR-204-5p/RUNX2 axis

A novel ceRNA network involving PCAT7/miR-204-5p/RUNX2 that drives glycolytic metabolism in BRCA is uncovered, advancing the understanding of epigenetic regulation in cancer metabolism and highlighting PCAT7 as a potential prognostic biomarker for BRCA patients, with future in vivo studies needed to further validate th...

Pengxiang Zhu, Wei Wu, Yi-Ning Han et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.